All In Biotech

Drug Trial Radar · NCT06695130

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 980 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

980

Actual

Start

Nov 18, 2024

Primary completion

Apr 3, 2026

Study completion Apr 3, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, and RIV + rC19 study groups to control for the number of injections and to maintain observer blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months * Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on Day(D) 01 * Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose) * The visit frequency for participants will be D01 and D30, and D09-D366 (telephone call) Number of Participants: Approximately 980 participants are expected to be randomized.

Conditions

  • COVID-19 Immunization
  • Influenza Immunization

Interventions

  • RIV (recombinant influenza vaccine)Biological

    Influenza, inactivated, split virus or surface antigen

  • rC19 (dose 1)Biological

    Protein subunit

  • RIV + rC19 (dose 1)Biological

    RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

  • RIV + rC19 (dose 2)Biological

    RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

  • RIV + rC19 (dose 3)Biological

    RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

  • RIV + rC19 (dose 4)Biological

    RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

  • Placebo (0.9% NaCl)Other

    Normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate adverse events (AEs)Time frame: Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination
  2. Number of participants with solicited injection site reactionsTime frame: Up to 7 each days after vaccination
  3. Number of participants with solicited systemic reactionsTime frame: Up to 7 days after each vaccination
  4. Number of participants with unsolicited AEsTime frame: Up to 28 days after each vaccination
  5. Number of participants with adverse events of special interest (AESIs)Time frame: Up to 180 days after each vaccination
  6. Number of participants with medical attended adverse events (MAAEs)Time frame: Up to 180 days after each vaccination
  7. Number of participants with MAAEs relating to predefined PIMDsTime frame: From Day 182 through 12 months following the last study vaccination
  8. Number of participants with serious adverse events (SAEs)Time frame: Up to 180 days after each vaccination
  9. Number of participants with related SAEsTime frame: From Day 182 through 12 months following the last study intervention
  10. Number of participants with MAAEs relating to predefined PIMDs that meet the criteria for SAEsTime frame: From Day 182 through 12 months following the last study vaccination
  11. Geometric mean (GM) of HAI titers in all participantsTime frame: At Day 01 and Day 30
  12. Geometric mean ratio (GMR) of HAI titers in all participantsTime frame: At Day 01 and Day 30
  13. GM of SARS-CoV-2 neutralizing titers in all participantsTime frame: At Day 01 and Day 30
  14. GMR of SARS-CoV-2 neutralizing titers ratio D30/D01 in all participantsTime frame: At Day 01 and Day 30

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Central Phoenix Medical Clinic- Site Number : 8400009

    Phoenix, Arizona

  • Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002

    Cerritos, California

  • Synexus Clinical Research US - Vista- Site Number : 8400010

    Vista, California

  • Optimal Research - Florida- Site Number : 8400006

    Melbourne, Florida

  • Synexus Clinical Research US - Orlando- Site Number : 8400007

    Orlando, Florida

  • Optimal Research - Illinois- Site Number : 8400008

    Peoria, Illinois

  • Synexus Clinical Research US - Evansville- Site Number : 8400004

    Evansville, Indiana

  • Walgreens Clinical Trials-Malden- Site Number : 8400012

    Malden, Massachusetts

  • Synexus Clinical Research US - Minneapolis- Site Number : 8400011

    Richfield, Minnesota

  • Synexus-Las Vegas- Site Number : 8400005

    Las Vegas, Nevada

  • Synexus Clinical Research US - Cincinnati- Site Number : 8400003

    Cincinnati, Ohio

  • Synexus Clinical Research US - Anderson- Site Number : 8400001

    Anderson, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.